synthetic pentadecapeptide
BPC-157
Answer
BPC-157 is not authorised on any of the 10 registers read, and 1 of them holds no reading for it. Highest trial phase: Phase 2. It has 4 registered trials, 2 of them running.
RegulatorTrial register10 regulators' registers, read 2026-08-31 to 2026-10-03 · ClinicalTrials.gov, read 2026-10-03
Not medical, legal or regulatory advice.
4 trials by status
Trial registerClinicalTrials.gov · read 2026-10-03 · 0 trials have posted results
Trials first submitted per year
Trial registerClinicalTrials.gov first-submitted date, last 2 years · read 2026-10-03. 2026 is not complete.
Status by jurisdiction
World map| Where | Status | Register | Read |
|---|---|---|---|
| United States | Not on the register | FDA, openfda | 2026-10-03 |
| European Union | Not on the register | EMA, ema | 2026-08-31 |
| United Kingdom | Not on the register | MHRA, uk-mhra | 2026-09-03 |
| Canada | Not on the register | Health Canada, ca-dpd | 2026-09-03 |
| Australia | Status unknown | TGA, au-artg | not read |
| Switzerland | Not on the register | Swissmedic, ch-swissmedic | 2026-09-03 |
| Brazil | Not on the register | ANVISA, br-anvisa | 2026-09-03 |
| Serbia | Not on the register | ALIMS, rs-alims | 2026-09-03 |
| Singapore | Not on the register | HSA, sg-hsa | 2026-09-03 |
| Turkey | Not on the register | TITCK, tr-titck | 2026-09-03 |
An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.
CHANGE ALERTS
Get an email when this changes
One email when the status of BPC-157 changes on the register. You confirm your address first.
ENFORCEMENT AND OFFICIAL ACTIONS
2 actions by named authorities
Enforcement actions, board positions and payer rules that name BPC-157, quoted from the source document. These are not approval decisions. This list shows the actions found so far. It is not a complete list: no authority publishes one.
| US-OHenforcement | Ohio Board of Pharmacy, 2026-04-16 During the inspection, [redacted] was found to possess multiple vials of the following illegal dangerous drugs, in either a white powder, purple powder, or clear liquid form, intended for injection, which were obtained from an unlicensed, foreign source: g. BPC 157/TB500 10mg, 4 vials; h. BPC-157 10mg, 8 vials;State of Ohio Board of Pharmacy, Order, Case No. A-2026-0037, Findings of Fact paragraphs 2(g)-2(h) · quoted with the party redacted |
|---|---|
| US-CAenforcement | California Board of Pharmacy, 2023-12-04 BPC-157 is derived from a particular stomach protein, but it is considered a synthetic product because it has a unique peptide chain that does not occur in nature. BPC-157 contains 15 amino acids and is therefore a peptide. It is a dangerous drug pursuant to Code section 4022.California Board of Pharmacy, First Amended Accusation and First Amended Statement of Issues, Case Nos. 7160 and 7171, paragraph 31 |
REGISTERED TRIALS
4 trials, newest first
| NCT07803250 | Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery not yet recruiting participants · register updated 2026-09-03 |
|---|---|
| NCT07752381 | A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery completed · register updated 2026-08-07 |
| NCT07437547 | BPC 157 for Acute Hamstring Muscle Strain Repair currently recruiting participants · register updated 2026-02-27 |
| NCT02637284 | PCO-02 - Safety and Pharmacokinetics Trial last verified some time ago; the register no longer confirms its status · register updated 2015-12-22 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.